Systemic therapy planning considerations – Prognostic tools and markers
In patients with breast cancer consider use of the PREDICT tool to estimate prognosis and the absolute benefits of adjuvant systemic therapy, recognising that the PREDICT tool is less accurate in some women and has not been validated in men or in an Australian population. Ki67 should be used in conjunction with other clinicopathological variables and should not be used alone in any patient to make treatment decisions.
Use the PREDICT tool to estimate prognosis and the absolute benefits of adjuvant therapy for women with invasive breast cancer
Useful Links
How this guidance was developed
This recommendation was adapted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted in September 2017 and used wording reflecting a strong recommendation (using GRADE methods) by the source guideline authors. The source recommendation was adapted by making it less directive, by replacing 'use' with 'consider' to reflect the Australian context, and by expanding the patient population from 'women' to 'all patients'.
Systemic therapy planning considerations – Prognostic tools and markers
In patients with breast cancer consider use of the PREDICT tool to estimate prognosis and the absolute benefits of adjuvant systemic therapy, recognising that the PREDICT tool is less accurate in some women and has not been validated in men or in an Australian population. Ki67 should be used in conjunction with other clinicopathological variables and should not be used alone in any patient to make treatment decisions.
Useful Links
This recommendation was adapted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted in September 2017 and used wording reflecting a strong recommendation (using GRADE methods) by the source guideline authors. The source recommendation was adapted by making it less directive, by replacing 'use' with 'consider' to reflect the Australian context, and by expanding the patient population from 'women' to 'all patients'.